103038-43-3

Basic information

• Product Name: Benzoic acid, 3-broMo-2-Methyl-, ethyl ester
• Synonyms: Benzoic acid, 3-broMo-2-Methyl-, ethyl ester
• CAS NO: 103038-43-3
• Molecular Formula: C₁₀H₁₁BrO₂
• Molecular Weight: 243.09714
• Mol File: 103038-43-3.mol
• Article Data: 8

Chemical Properties

• Appearance: /
• CAS DataBase Reference: Benzoic acid, 3-broMo-2-Methyl-, ethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: Benzoic acid, 3-broMo-2-Methyl-, ethyl ester(103038-43-3)
• EPA Substance Registry System: Benzoic acid, 3-broMo-2-Methyl-, ethyl ester(103038-43-3)

Safety Data

• Hazardous Substances Data: 103038-43-3(Hazardous Substances Data)

Usage

General Description

Benzoic acid, 3-bromo-2-methyl-, ethyl ester is a chemical compound commonly used as a flavoring agent and preservative in food and beverages. It is also used in the production of synthetic flavors and fragrances. Benzoic acid, 3-broMo-2-Methyl-, ethyl ester is a derivative of benzoic acid, a naturally occurring compound found in various plants. The ethyl ester form of this compound is commonly used in the formulation of cosmetic and personal care products. However, it is important to note that this chemical should be handled with care and used in accordance with safety guidelines due to its potential hazardous properties.

Upstream product

• 7787-70-4 copper(I) bromide 
• 52780-15-1 3'-bromo-2'-methylbenzonitrile 
• 64-17-5 ethanol 
• 76006-33-2 3-bromo-2-methylbenzoic acid 

Downstream Products

• 65276-20-2 2,3,2',3'-tetramethyl-bibenzyl 
• 112299-62-4 1-bromo-3-(bromomethyl)-2-methylbenzene 
• 92396-98-0 3,3'-Dibromo-2,2'-dimethyldiphenylethane 
• 101783-93-1 1,2-bis(3'-bromomethyl-2'-methylphenyl)ethane 
• 92396-99-1 3,3'-Dicarboxy-2,2'-dimethyldiphenylethane 
• 92397-00-7 3,3'-Dicarbaethoxy-2,2'-dimethyl-bibenzyl 
• 92397-01-8 3,3'-bis-(hydroxymethyl)-2,2'-dimethyldiphenylethane 
• 104175-24-8 ethyl 2,3-dimethylbenzoate 
• 76350-90-8 (2-methyl-[1,1′-biphenyl]-3-yl)methanol 
• 116175-22-5 [2-methyl-(1,1'-biphenyl)-3-yl]-methyl bromide 
• 115363-11-6 2-methyl-[1,1’-biphenyl]-3-carboxylic acid 

Relevant articles and documents

Design, Synthesis, and Evaluation of o-(Biphenyl-3-ylmethoxy)nitrophenyl Derivatives as PD-1/PD-L1 Inhibitors with Potent Anticancer Efficacy in Vivo

Two series of novel o-(biphenyl-3-ylmethoxy)nitrophenyl compounds (A1-31 and B1-17) were designed as programmed cell death protein 1 (PD-1)/PD-ligand 1 (PD-L1) inhibitors. All compounds showed significant inhibitory activity with IC50 values ranging from 2.7 to 87.4 nM except compound A17, and compound B2 displayed the best activity. Further experiments showed that B2 bound to the PD-L1 protein without obvious toxicity in Lewis lung carcinoma (LLC) cells. Furthermore, B2 significantly promoted interferon-gamma secretion in a dose-dependent manner in vitro and in vivo. Especially, B2 exhibited potent in vivo anticancer efficacy in an LLC-bearing allograft mouse model at a low dose of 5 mg/kg, which was more active than BMS-1018 (tumor growth inhibition rate: 48.5% vs 17.8%). A panel of immunohistochemistry and flow cytometry assays demonstrated that B2 effectively counteracted PD-1-induced immunosuppression in the tumor microenvironment, thereby triggering antitumor immunity. These results indicate that B2 is a promising PD-1/PD-L1 inhibitor worthy of further development.

Design, synthesis, and biological evaluation of structurally modified isoindolinone and quinazolinone derivatives as hedgehog pathway inhibitors

The Hedgehog (Hh) signaling pathway is associated with diverse aspects of cellular events, such as cell migration, proliferation, and differentiation throughout embryonic development and tissue patterning. An abnormal Hh signaling pathway is linked to numerous human cancers, including basal cell carcinoma (BCC), medulloblastoma (MB), lung cancer, prostate cancer, and ovarian cancer, and it is therefore a promising target in cancer therapy. Using a structure-hopping approach, we designed new Hh signaling pathway inhibitors with isoindolinone or quinazolinone moieties, which were synthesized and biologically evaluated using an 8xGli-luciferase (Gli-Luc) reporter assay in NIH3T3 cells. Compounds 9–11 and 14 with isoindolinone scaffolds demonstrated moderate Hh inhibitory activity; whereas quinazolinone derivatives 24, 29, 32, 34, and 35 exhibited good potency with submicromolar IC50values and the analog 28 showed nanomolar IC50value. Although sonidegib shows a decrease in inhibitory effect on vismodegib resistance-conferring Smo mutants, the structurally modified new compounds not only possess the pharmacophoric properties of Hh pathway inhibition but also preserve the suppressive potency in drug-resistant Smo mutants. Mechanistically, quinazolinone derivatives 28 and 34 suppress Hh signaling by blocking Smo and Gli translocation into the cilia, similar to vismodegib and sonidegib. Additionally, the human microsomal stability of the representative analogs 28 and 34 were determined to be comparable to that of the reference compound sonidegib. Thus, these new scaffolds can serve as a platform for the development of novel cancer therapeutics targeting the Hh pathway.

ISOPROPYL TRIAZOLO PYRIDINE COMPOUNDS

The present invention provides a compound of the Formula (I) below: Wherein R1 is selected from the group consisting of H, CH3, CN, CH2CN, C(CH3)2CN, and F; R2 is selected from the group consisting of H, O(C1-C3alkyl)R5, CH2CN, and CN; R3 is selected from the group consisting of H, OCH3, CN, C(CH3)2CN, and CH2CN; R4 is selected from the group consisting of H and CH3; R5 is selected from the group consisting of H, CN, C(CH3)2CN, OCH3, S(O)2CH3, and C(CH3)2OH; provided that at least one selected from the group consisting of R1, R2, R3 and R4 is H; or a pharmaceutically acceptable salt thereof, methods of treating diabetes using the compound and a process for preparing the compound.